立克次氏體2點(diǎn)IgM免疫熒光玻片試劑盒

Rickettsia 2-Antigen MIF IgM kit

廣州健侖生物科技有限公司

主要用途：用于檢測人血清中的立克次氏體 2 點(diǎn) IgM 抗體

產(chǎn)品規(guī)格：12 孔/張,10 張/盒

主要產(chǎn)品包括：包柔氏螺旋體菌、布魯氏菌、貝納特氏立克次體、土倫桿菌、鉤端螺旋體、新型立克次體、恙蟲病、立克次體、果氏巴貝西蟲、馬焦蟲、牛焦蟲、利什曼蟲、新包蟲、弓形蟲、貓流感病毒、貓冠狀病毒、貓皰疹病毒、犬瘟病毒、犬細(xì)小病毒等病原微生物的 IFA、MIF、ELISA試劑。

立克次氏體2點(diǎn)IgM免疫熒光玻片試劑盒

我司還提供其它進(jìn)口或國產(chǎn)試劑盒：登革熱、瘧疾、西尼羅河、立克次體、無形體、蜱蟲、恙蟲、利什曼原蟲、RK39、漢坦病毒、深林腦炎、流感、A鏈球菌、合胞病毒、腮病毒、乙腦、寨卡、黃熱病、基孔肯雅熱、克錐蟲病、違禁品濫用、肺炎球菌、軍團(tuán)菌、化妝品檢測、食品安全檢測等試劑盒以及日本生研細(xì)菌分型診斷血清、德國SiFin診斷血清、丹麥SSI診斷血清等產(chǎn)品。

歡迎咨詢

歡迎咨詢2042552662

二維碼掃一掃

【公司名稱】 廣州健侖生物科技有限公司
【】    楊永漢 
【】 
【騰訊 】 2042552662
【公司地址】 廣州清華科技園創(chuàng)新基地番禺石樓鎮(zhèn)創(chuàng)啟路63號(hào)二期2幢101-3室
【企業(yè)文化】

預(yù)后良好的患者可幸免進(jìn)行帶有嚴(yán)重副作用的侵入性治療，但不對(duì)侵入性腫瘤進(jìn)行侵入治療或可導(dǎo)致死亡。癌癥之所以致命，在很大程度上是由于其發(fā)生了轉(zhuǎn)移，從一個(gè)器官或組織轉(zhuǎn)移到另一個(gè)器官或組織。癌癥致死絕大多數(shù)與轉(zhuǎn)移有關(guān)。
對(duì)于抗原抗體癌來說，被稱為“上皮間質(zhì)轉(zhuǎn)化”的過程助推了這種轉(zhuǎn)移。上皮細(xì)胞系附著在與環(huán)境接觸的皮膚和胃腸道中。間質(zhì)細(xì)胞是胚胎組織和結(jié)締組織中的一種細(xì)胞類型，其在那里形成非常松散的。腫瘤細(xì)胞失去成熟上皮細(xì)胞的特性(如附著于環(huán)境的能力)，獲得間質(zhì)細(xì)胞的能力，使其能夠輕松地在細(xì)胞間流動(dòng)并進(jìn)入血液，從而遷移到遠(yuǎn)處的器官和組織。
加拿大麥吉爾大學(xué)喬西·尤西尼-西格爾主持的新研究表明，p66ShcA蛋白富含于經(jīng)歷了上皮間質(zhì)細(xì)胞轉(zhuǎn)移的抗原抗體癌中。在所有抗原抗體癌類型中，p66ShcA表達(dá)水平的升高與上皮間質(zhì)細(xì)胞轉(zhuǎn)化基因的表達(dá)密切相關(guān)。因此，p66ShcA可用作確定各種分子亞型抗原抗體癌預(yù)后的*標(biāo)記。
抗原抗體癌至少有5種亞型，其中每一種都與不同預(yù)后結(jié)果相關(guān)。早期研究表明，亞型具有異質(zhì)性，因此基于亞型的預(yù)后結(jié)果不太可靠。研究人員表示，對(duì)造成腫瘤細(xì)胞異質(zhì)性和轉(zhuǎn)移基本機(jī)制的深入了解，有助于更好地明確疾病的預(yù)后發(fā)展并提出改善治療效果的方法。

Patients with good prognosis can be spared aggressive treatment with serious side effects, but not invasive treatment of invasive tumors or can lead to death. The cancer is fatal, in large part because of its metastasis, its transfer from one organ or tissue to another organ or tissue. The vast majority of cancer death and metastasis.
For antigen-antibody cancers, a process called "epithelial mesenchymal transition" helps to promote this metastasis. Epithelial cell lines attach to the environment in contact with the skin and gastrointestinal tract. Stromal cells are a type of cell in embryonic tissue and connective tissue where they form a very loose connection. Tumor cells lose the properties of mature epithelial cells (such as their ability to attach to the environment) and gain the ability of interstitial cells to migrate easily to and from the bloodstream to distant organs and tissues.
New research led by Josie Ussini-Siegel of McGill University in Canada shows that the p66ShcA protein is enriched in antigen-antibody cancers that have undergone epithelial mesenchymal cell metastasis. In all antigen-antibody cancer types, the increased expression of p66ShcA is closely related to the expression of epithelial-derived stromal cells. Therefore, p66ShcA can be used as a first choice marker for determining the prognosis of various molecular subtype antigens.
Antigen Antibody The cancer has at least 5 subtypes, each of which is associated with a different outcome. Early studies have shown that subtypes are heterogeneous, so prognosis based on subtypes is less reliable. The researchers said that an in-depth understanding of the underlying mechanisms responsible for tumor cell heterogeneity and metastasis can help to better define the prognosis of the disease and suggest ways to improve the outcome.